top of page
The Sage Group is attending BioEurope in Vienna, Austria, from November 3-5, 2025! Please click here to meet!
See Latest News!
GLOBAL LIFE SCIENCES DEALMAKERS: 30+ YEARS. 300+ CLIENTS & TRANSACTIONS. BILLIONS IN VALUE.
The Sage Group
Why Sage?
About
Track Record
Locations
Added Value
Sage Clients
Testimonials
SAGEIQ
Services
M & A
Licensing
Sage Global
Sage APAC
Sage China
Sage Japan
Sage India
Team
Meet Us!
News
Downloads
Contact
More
Use tab to navigate through the menu items.
Sage Group News
Opportunity to License XMVA09, A Phase I First-in-class Intravitreal AAV Therapy Expressing Anti-VEGF and ANG2 Bispecific Antibody
Starrygene ( https://www.starrygene.com/ ) is a clinical stage biotechnology company based in China, focused on XMVA09, a novel...
Opportunity to License SP16, A Novel Treatment For Acute Kidney Injury (AKI)
Serpin Pharma (“Serpin”) is an anti-inflammatory/immunology company focused on developing its patented (CoM and use) SP-16 LRP1 agonist...
Opportunity to Partner Novel VHH Multi-Specific Antibodies Targeted at Solid and Hematologic Tumors
Our client, Starmab Biomed Inc (“Starmab” or the “Company”), is a US/China-based biotech company headquartered at Beijing Zhongguancun...
bottom of page